Navigation Links
EYLEA™ (aflibercept injection) Submitted in Japan for Marketing Authorization for the Treatment of Wet Age-Related Macular Degeneration
Date:6/28/2011

tors.  EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.

Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA with Phase 3 programs for the treatment of the neovascular form of age-related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV).

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet AMD in the U.S. in February 2011 and received a Priority Review designation.  Under Priority Review, the target date for an FDA decision on the EYLEA BLA is August 20, 2011.  Bayer HealthCare submitted an application for marketing authorization in Europe in June 2011.

About Regeneron Pharmaceuticals

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health car
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
2. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
3. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
4. Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation
5. Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
8. Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
9. Reverse NanoJapan: Rice to host 25-30 Japanese students
10. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
11. Epichem and AR Brown Sign Exclusive Distribution Agreement for Japan, Taiwan, China and South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
(Date:12/24/2014)... 2014 The report provides basic ... classification, application and industry overview. This report also ... structure. Production is separated by regions, technology and ... equipment, downstream client survey, marketing channels, industry development ...
Breaking Biology Technology:Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... at the Cambridge University have discovered that freshwater algae ... each other, miraculously held together only by the fluid ... today in the journal Physical Review Letters . ... consists of approximately 1,000 cells arranged on the surface ...
... Kendle (Nasdaq: KNDL ), a leading, global ... not meet analyst expectations for the first quarter of ... unprecedented biopharmaceutical industry conditions, which are resulting in longer ... fewer new requests for proposals and an increase in ...
... --BRISBANE, Calif., April 20 InterMune, Inc. (Nasdaq: ... host a live webcast of a discussion of the INFORM-1 ... at 7:00 p.m. CEST (1:00 p.m. EDT). Participating in ... the INFORM-1 trial. Members of management from Roche, InterMune ...
Cached Biology Technology:Scientists discover 'dancing' algae 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 2Kendle to Host Conference Call to Discuss Revised 2009 Outlook 3InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25 2
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... CAMBRIDGE, Mass. (April 2, 2009) Whitehead Institute researchers have ... have further clarified the role prions play in the inheritance ... in the field is are the prions functional are ... disease, as in "mad cow," disease in mammals," says Randal ...
... Since the days of Charles Darwin, researchers are interested ... the development of animal and plant species during their ... has already come quite a long way. But there ... animal groups that made their apparation very early in ...
... directly affect human survival and food security, especially as ... groups of social insects to cultivate crops, have harvested ... 50 million years. New results from the Smithsonian show ... combat fungi coming into the nest inside leaves, thus ...
Cached Biology News:Redefining what it means to be a prion 2Redefining what it means to be a prion 3Early family ties: No sponge in the human family tree 2Early family ties: No sponge in the human family tree 3Food security for leaf-cutting ants: Workers and their fungus garden reject endophyte invaders 2
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
Goat anti-mouse gamma chain-HRP...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Human IFN-Gamma Receptor Chain 2 (beta chain) [CD119], Rabbit serum, NON-neutralizing polyclonal antibody...
Biology Products: